Larazotide Acetate vs P21
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
Larazotide AcetateCognitive EnhancementAnti-Aging & Longevity
P21- Summary
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
- Half-Life
- Local gut action; minimal systemic exposure
- Not well characterized; likely short, but neurogenic effects persist long after administration
- Admin Route
- Oral
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 0.5-2 mg
- 100–500 mcg
- Frequency
- 3x daily
- Once daily
- Key Benefits
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Promotes hippocampal neurogenesis
- Enhances spatial memory and learning
- Increases BDNF expression
- Reduces amyloid-beta plaque formation (animal models)
- Anti-tau pathology potential
- Cognitive enhancement without stimulant effects
- Potential therapeutic for Alzheimer's and cognitive aging
- Side Effects
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Generally well tolerated in animal studies
- Limited human clinical data
- Injection site reactions
- Potential mild fatigue at initiation
- Stacks With
- —
- —